VBL Therapeutics (VBLT) Misses Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to VBL Therapeutics (VBLT) Misses Q3 EPS by 10c

VBL Therapeutics Announces Third Quarter 2015 Financial Results and Provides Business Update

November 12, 2015 7:01 AM EST

Initiated GLOBE pivotal Phase 3 trial of VB-111 in recurrent glioblastoma (rGBM)

Reported positive, final Phase 2 data of VBL-111 in rGBM at the European Cancer Conference (ECC) 2015

Raised $15 million gross proceeds in an underwritten offering, expected to fund operations through readout of results from the pivotal GLOBE trial

TEL AVIV, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of... More